Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection (Q33291670)

25 July 2017

Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection (English)

1 reference

eradication of infectious diseases

25 July 2017

1 reference

1 reference

Helicobacter pylori infectious disease

inferred from title

1 reference

Francisco Rivas-Ruiz

11

0 references

author name string

José M Navarro-Jarabo

1

1 reference

25 July 2017

Nuria Fernández

2

1 reference

25 July 2017

Francisca L Sousa

3

1 reference

25 July 2017

Encarnación Cabrera

4

1 reference

25 July 2017

Manuel Castro

5

1 reference

25 July 2017

Luz M Ramírez

6

1 reference

25 July 2017

Robin Rivera

7

1 reference

25 July 2017

Esther Ubiña

8

1 reference

25 July 2017

Francisco Vera

9

1 reference

25 July 2017

Isabel Méndez

10

1 reference

25 July 2017

José L Moreno

12

1 reference

25 July 2017

Emilio Perea-Milla

13

1 reference

25 July 2017

25 July 2007

1 reference

25 July 2017

1 reference

25 July 2017

7

1 reference

25 July 2017

31

1 reference

Creative Commons Attribution 2.0 Generic

25 July 2017

start time

25 July 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1471-230x-7-31

0 references

cites work

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Regular review: treatment of Helicobacter pylori infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Treatment after failure: the problem of "non-responders".

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Rifampin and rifabutin resistance mechanism in Helicobacter pylori

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Treatment of antibiotic-resistant Helicobacter pylori.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

Rifabutin-based Helicobacter pylori eradication 'rescue therapy'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

Comparison between two 13C-urea breath tests for the diagnosis of Helicobacter pylori infection: isotope ratio mass spectrometer versus infrared spectrometer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-7-31

[An update on the antibiotic therapy of tuberculosis]

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1941741

Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole

31 October 2018

1 reference

12 December 2020

Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures

1 reference

12 December 2020

In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin

1 reference

12 December 2020

Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens

1 reference

12 December 2020

Isotope-selective non-dispersive infrared spectrometry for detection of Helicobacter pylori infection with 13C-urea breath test

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-230X-7-31

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference